Home | Welcome to Contract Pharma   
Last Updated Wednesday, May 27 2015


Financial Reports: Tranzyme Pharma

Published April 1, 2013
Related Searches: Phase III Pharma
Tranzyme Pharma

4Q Revenues: $1.6 million (-27%)

4Q Loss: $4.9 million (loss of $8.0 million 4Q11)

FY Revenues: $8.4 million (-17%)

FY Loss: $22.8 million (loss of $22.2 million FY11)

Comments: Decrease in revenue was primarily due to changes in the amortization period for revenue from the Bristol-Myers Squibb collaboration. R&D expenses were $3.5 million in the quarter compared to $7.7 million in 4Q11. The decrease was primarily due to a reduction in Phase III trial expenses for ulimorelin and our Phase IIb trial activities for TZP-102.

blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On